Table 1.
Baseline Characteristics.
| Patient No. |
Genotype | race | Age (yr) |
gender | Weight (kg) |
CD4 (cells/mm3) |
HIV RNA (cp/ml) |
HAART | Metavir Fibrosis Stage |
|---|---|---|---|---|---|---|---|---|---|
| 1* | 3 | W | 50 | M | 70 | 700 | 245 | AZT/ LAM | F1A2 |
| 2* | 3 | W | 34 | M | 66 | 533 | 405 | no | F1A 2 |
| 3* | 3 | W | 40 | M | 76 | 653 | 1850 | AZT/ LAM/ EFZ | F2A2 |
| 6* | 3 | B | 32 | M | 67 | 441 | < 50 | no | F1A1 |
| 7* | 3 | W | 34 | F | 52 | 455 | 1590 | AZT/ LAM/ EFZ | F0A1 |
| 4* | 1 | B | 56 | M | 60 | 611 | 325 | D4T/ LAM/ NFV | F4A1 |
| 5* | 1 | B | 37 | M | 86 | 400 | 9930 | no | F2A2 |
| 8 | 3 | W | 42 | M | 92 | 327 | < 50 | AZT/ LAM/ NFV | F4A1 |
| 9 | 3 | W | 35 | M | 71 | 664 | < 50 | AZT/ LAM/ EFZ | F2A2 |
| 13 | 3 | W | 39 | M | 89 | 436 | < 50 | AZT/ LAM/ NFV | F2A3 |
| 10 | 1 | B | 49 | F | 65 | 519 | 3920 | no | F0A1 |
| 11 | 1 | W | 39 | F | 76 | 587 | 170 | AZT/ LAM/ NFV | F0A1 |
| 12 | 1 | B | 43 | M | 60 | 612 | < 50 | AZT/ LAM/ NFV | F4A1 |
| 14 | 1 | W | 42 | M | 65 | 672 | < 50 | D4T/ LAM/ NVP | F2A2 |
| 15 | 1 | W | 35 | M | 69 | 690 | 1630 | no | F0A2 |
| 16 | 1 | B | 38 | M | 54 | 430 | < 50 | D4T / LAM/ LPVr | F1A2 |
| 17 | 1 | B | 47 | M | 58 | 929 | 792 | D4T/ LAM/ EFZ/ NFV | F1A2 |
| 18 | 1 | W | 39 | M | 79 | 579 | < 50 | AZT/ DDI/ NVP | F0A1 |
| 19 | 1 | W | 48 | M | 54 | 418 | 7350 | AZT/ LAM/ EFZ | F1A1 |
| 20 | 1 | B | 54 | M | 62 | 739 | < 50 | AZT/ LAM/ NVP | F0A1 |
| 21 | 1 | B | 36 | M | 65 | 956 | < 50 | AZT/ LAM/ NFV | F0A1 |
| p value | 0.056 @ | 1.0 | 0.37 | 1.0 | 0.8 | 0.5 | NS | 0.28 | 1.0 |
*
SVR. P values for the difference between SVRs and non-SVRs;
@
with Chi-square test p=0.026;
SD, standard deviation; W, white; B, black; M, male; HAART, highly active antiretroviral therapy; AZT, zidovudine; LAM, lamivudine; EFZ, efavirenz; D4T, stavudine; NFV, nelfinavir; LPVr, lopinavirritonavir; NVP, nevirapine; DDI, didanosine; Cirrhosis was defined based on Metavir fibrosis stage score, i.e., F4.